(Q28271849)

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Monitoring drug resistance in leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Kinetoplastida: new therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Liposomal amphotericin B for the treatment of visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Single-dose liposomal amphotericin B (AmBisome®) for the treatment of visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Single-dose liposomal amphotericin B for visceral leishmaniasis in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Pentamidine dosage: a base/salt confusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Development of miltefosine as an oral treatment for leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Trial of oral miltefosine for visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Antiprotozoal activities of phospholipid analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Analogs of alkyllysophospholipids: Chemistry, effects on the molecular level and their consequences for normal and malignant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Cytotoxicity of ester and ether lysophospholipids on Leishmania donovani promastigotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

A poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appeal

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Leishmaniasis in the United States: treatment in 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Optimal dosing of miltefosine in children and adults with visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Who is a typical patient with visceral leishmaniasis? Characterizing the demographic and nutritional profile of patients in Brazil, East Africa, and South Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Drug policy for visceral leishmaniasis: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Quantification of CLR1401, a novel alkylphosphocholine anticancer agent, in rat plasma by hydrophilic interaction liquid chromatography-tandem mass spectrometric detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Inward translocation of the phospholipid analogue miltefosine across Caco-2 cell membranes exhibits characteristics of a carrier-mediated process

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Modulation of intestinal barrier properties by miltefosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steady-state treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Administration of miltefosine and meglumine antimoniate in healthy dogs: clinicopathological evaluation of the impact on the kidneys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Ether phospholipids and glycosylinositolphospholipids are not required for amastigote virulence or for inhibition of macrophage activation by Leishmania major.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Ether--lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether--lipid analogues in Leishmania

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Miltefosine affects lipid metabolism in Leishmania donovani promastigotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Choline transport in Leishmania major promastigotes and its inhibition by choline and phosphocholine analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Possible mechanism of miltefosine-mediated death of Leishmania donovani

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Miltefosine induces metacaspase and PARP genes expression in Leishmania infantum

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Miltefosine induces apoptosis-like cell death in yeast via Cox9p in cytochrome c oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Hexadecylphosphocholine selectively upregulates expression of intracellular adhesion molecule-1 and class I major histocompatibility complex antigen in human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Miltefosine efficiently eliminates Leishmania major amastigotes from infected murine dendritic cells without altering their immune functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Critical role for phosphoinositide 3-kinase gamma in parasite invasion and disease progression of cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

The p110delta isoform of phosphatidylinositol 3-kinase controls susceptibility to Leishmania major by regulating expansion and tissue homing of regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Effects of hexadecylphosphocholine on phosphatidylcholine and phosphatidylserine metabolism in human lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Hexadecylphosphocholine interferes with the intracellular transport of cholesterol in HepG2 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Distinctive molecular signaling in triple-negative breast cancer cell death triggered by hexadecylphosphocholine (miltefosine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Efficacy of anticancer alkylphosphocholines in Trypanosoma brucei subspecies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Effects of miltefosine and other alkylphosphocholines on human intestinal parasite Entamoeba histolytica

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Cytotoxic activities of alkylphosphocholines against clinical isolates of Acanthamoeba spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

In vitro activity of hexadecylphosphocholine (miltefosine) against metronidazole-resistant and -susceptible strains of Trichomonas vaginalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Combination of cell culture and quantitative PCR for screening of drugs against Cryptosporidium parvum

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

In a trial of the use of miltefosine to treat HIV-related cryptosporidiosis in Zambian adults, extreme metabolic disturbances contribute to high mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Miltefosine, a promising novel agent for schistosomiasis mansoni

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

In vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic streptococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

In vitro and in vivo activity of miltefosine against penicillin-sensitive and -resistant Streptococcus pneumoniae strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Anti-acanthamoeba efficacy and toxicity of miltefosine in an organotypic skin equivalent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Targeting the PI3K/Akt cell survival pathway to induce cell death of HIV-1 infected macrophages with alkylphospholipid compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Low plasma membrane expression of the miltefosine transport complex renders Leishmania braziliensis refractory to the drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Disruption of the lipid-transporting LdMT-LdRos3 complex in Leishmania donovani affects membrane lipid asymmetry but not host cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Alkyl-lysophospholipid resistance in multidrug-resistant Leishmania tropica and chemosensitization by a novel P-glycoprotein-like transporter modulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Combination of suboptimal doses of inhibitors targeting different domains of LtrMDR1 efficiently overcomes resistance of Leishmania spp. to Miltefosine by inhibiting drug efflux

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

A novel ATP-binding cassette transporter from Leishmania is involved in transport of phosphatidylcholine analogues and resistance to alkyl-phospholipids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Multiple mutations in heterogeneous miltefosine-resistant Leishmania major population as determined by whole genome sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Leishmania resistance to miltefosine associated with genetic marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Miltefosine: oral treatment of leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

MDR1 causes resistance to the antitumour drug miltefosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Effects of miltefosine on membrane permeability and accumulation of [99mTc]-hexakis-2-methoxyisobutyl isonitrile, 2-[18F]fluoro-2-deoxy-D-glucose, daunorubucin and rhodamine123 in multidrug-resistant and sensitive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

In vitro and in vivo interactions between miltefosine and other antileishmanial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Combination therapy for visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Designing and reporting clinical trials on treatments for cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Oral miltefosine in post-kala-azar dermal leishmaniasis--experience in three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Topical treatment with hexadecylphosphocholine (Miltex) efficiently reduces parasite burden in experimental cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal--the challenges for diagnosis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Oral miltefosine for Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Miltefosine for new world cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Efficacy of Miltefosine for the Treatment of American Cutaneous Leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275

Synthesis, antifungal and antimicrobial activity of alkylphospholipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKS275